CN101065358A - 3-芳基氨基吡啶衍生物 - Google Patents
3-芳基氨基吡啶衍生物 Download PDFInfo
- Publication number
- CN101065358A CN101065358A CNA2005800406885A CN200580040688A CN101065358A CN 101065358 A CN101065358 A CN 101065358A CN A2005800406885 A CNA2005800406885 A CN A2005800406885A CN 200580040688 A CN200580040688 A CN 200580040688A CN 101065358 A CN101065358 A CN 101065358A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- fluoro
- iodo
- isonicotinamide
- phenyl amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
实施例# | MEK抑制 | IC50[μM]C26 | IC50[μM]A375 | IC50 [μM]Miapaca |
1 | ++ | |||
2 | ++ | |||
3 | ++ | |||
4 | ++ | ++ | n.d. | |
5 | ++ | + | ++ | n.d. |
6 | + | |||
7 | ++ | ++ | ++ | ++ |
8 | ++ | ++ | ++ | ++ |
9 | ++ | + | ++ | n.d. |
10 | ++ | + | ++ | ++ |
11 | ++ | ++ | ++ | ++ |
12 | ++ | ++ | ++ | ++ |
13 | ++ | ++ | ++ | ++ |
14 | ++ | ++ | ++ | ++ |
15 | ++ | ++ | ++ | ++ |
16 | ++ | ++ | ++ | ++ |
17 | ++ | ++ | ++ | ++ |
18 | ++ | ++ | ++ | ++ |
19 | ++ | + | ++ | ++ |
20 | ++ | ++ | ++ | ++ |
21 | ++ | + | ++ | + |
22 | ++ | ++ | ++ | ++ |
23 | ++ | ++ | ++ | ++ |
24 | ++ | ++ | ++ | ++ |
25 | ++ | ++ | ++ | ++ |
26 | ++ | + | ++ | + |
27 | ++ | + | + | + |
28 | ++ | + | ++ | + |
29 | ++ | + | ++ | + |
30 | ++ | ++ | ++ | ++ |
31 | ++ | ++ | ++ | ++ |
32 | ++ | ++ | ++ | ++ |
33 | ++ | ++ | ++ | ++ |
34 | ++ | + | ++ | + |
35 | ++ | ++ | ++ | ++ |
36 | ++ | ++ | ++ | ++ |
37 | ++ | n.d. | n.d. | n.d. |
38 | + | n.d. | n.d. | n.d. |
39 | ++ | ++ | ++ | ++ |
40 | ++ | + | ++ | + |
41 | ++ | ++ | ++ | ++ |
42 | ++ | + | ++ | + |
43 | ++ | + | ++ | + |
44 | ++ | + | ++ | + |
45 | ++ | + | ++ | + |
46 | ++ | + | ++ | + |
47 | ++ | ++ | ++ | ++ |
48 | ++ | ++ | ++ | ++ |
49 | ++ | ++ | ++ | ++ |
50 | ++ | + | ++ | + |
51 | ++ | + | ++ | ++ |
52 | + | n.d. | n.d. | n.d. |
53 | ++ | ++ | ++ | ++ |
54 | + | + | ||
55 | ++ | + | ++ | + |
56 | + | + | ++ | + |
57 | + | n.d. | n.d. | n.d. |
58 | ++ | ++ | ++ | ++ |
59 | + | n.d. | n.d. | n.d. |
60 | ++ | ++ | ++ | ++ |
61 | ++ | + |
62 | ++ | + | ++ | |
63 | ++ | ++ | ||
64 | ++ | + | ++ | + |
65 | ++ | + | ++ | + |
66 | ++ | ++ | ||
67 | ++ | ++ | ++ | ++ |
68 | ++ | ++ | ++ | ++ |
69 | ++ | + | ++ | |
70 | ++ | ++ | ++ | ++ |
71 | ++ | + | ++ | + |
72 | ++ | + | ++ | + |
73 | ++ | |||
74 | ++ | + | ++ | + |
75 | ++ | ++ | ++ | ++ |
76 | ++ | + | ++ | + |
77 | ++ | + | ++ | + |
78 | ++ | + | ++ | |
79 | ++ | ++ | ++ | ++ |
80 | ++ | ++ | + | |
81 | ++ | + | ++ | + |
82 | ++ | + | ++ | + |
83 | ++ | ++ | ++ | ++ |
84 | ++ | + | ++ | |
85 | ++ | + | ++ | + |
86 | ++ | + | ++ | + |
87 | ++ | ++ | + | |
88 | ++ | + | + | + |
89 | + | n.d. | n.d. | n.d. |
90 | ++ | ++ | ++ | ++ |
91 | ++ | + | ++ | + |
92 | ++ | + | ++ | + |
93 | ++ | + | ++ | + |
94 | ++ | + | ||
95 | ++ | |||
96 | ++ | ++ | ++ | ++ |
97 | ++ | ++ | ++ | ++ |
98 | ++ | + | ++ | + |
99 | ++ | + | ++ | + |
100 | ++ | + | ++ | + |
101 | ++ | + | ++ | + |
102 | ++ | + | ++ | + |
103 | ++ | n.d. | n.d. | n.d. |
104 | ++ | n.d. | n.d. | n.d. |
105 | ++ | n.d. | n.d. | n.d. |
106 | ++ | n.d. | n.d. | n.d. |
107 | ++ | n.d. | n.d. | n.d. |
108 | ++ | n.d. | n.d. | n.d. |
109 | ++ | n.d. | n.d. | n.d. |
110 | ++ | n.d. | n.d. | n.d. |
111 | ++ | n.d. | n.d. | n.d. |
112 | ++ | n.d. | n.d. | n.d. |
113 | ++ | n.d. | n.d. | n.d. |
114 | ++ | n.d. | n.d. | n.d. |
115 | ++ | n.d. | n.d. | n.d. |
116 | ++ | n.d. | n.d. | n.d. |
117 | n.d. | n.d. | n.d. | n.d. |
118 | + | n.d. | n.d. | n.d. |
119 | + | n.d. | n.d. | n.d. |
120 | n.d. | n.d. | n.d. | |
121 | ++ | n.d. | n.d. | n.d. |
122 | n.d. | n.d. | n.d. | |
123 | ++ | n.d. | n.d. | n.d. |
124 | ++ | + | n.d. | n.d. |
125 | ++ | n.d. | n.d. | n.d. |
126 | + | n.d. | n.d. | n.d. |
127 | n.d. | n.d. | n.d. | |
128 | ++ | n.d. | n.d. | n.d. |
129 | ++ | n.d. | n.d. | n.d. |
实施例# | HLMt1/2[min] | RLMt1/2[min] | MLMt1/2[min] | Caco A-B | Caco B-A |
4 | ++ | ++ | n.d. | n.d. | n.d. |
9 | +++ | +++ | +++ | + | ++ |
123 | ++ | + | n.d. | n.d. | n.d. |
127 | +++ | +++ | + | ++ | ++ |
128 | +++ | ++ | n.d. | ++ | ++ |
129 | +++ | ++ | +++ | ++ | ++ |
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04024967.4 | 2004-10-20 | ||
EP04024967 | 2004-10-20 | ||
PCT/EP2005/011257 WO2006045514A1 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101065358A true CN101065358A (zh) | 2007-10-31 |
CN101065358B CN101065358B (zh) | 2015-03-11 |
Family
ID=34927054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200580040688.5A Active CN101065358B (zh) | 2004-10-20 | 2005-10-19 | 3-芳基氨基吡啶衍生物 |
Country Status (22)
Country | Link |
---|---|
US (4) | US7956191B2 (zh) |
EP (1) | EP1802579B1 (zh) |
JP (1) | JP5214971B2 (zh) |
KR (1) | KR101318012B1 (zh) |
CN (1) | CN101065358B (zh) |
AR (1) | AR051248A1 (zh) |
AU (1) | AU2005298932B2 (zh) |
BR (1) | BRPI0518192B8 (zh) |
CA (1) | CA2582247C (zh) |
CY (1) | CY1114861T1 (zh) |
DK (1) | DK1802579T3 (zh) |
EA (1) | EA013212B1 (zh) |
ES (1) | ES2444866T3 (zh) |
HK (1) | HK1107347A1 (zh) |
MX (1) | MX2007004781A (zh) |
NO (1) | NO339639B1 (zh) |
PL (1) | PL1802579T3 (zh) |
PT (1) | PT1802579E (zh) |
SI (1) | SI1802579T1 (zh) |
UA (1) | UA94571C2 (zh) |
WO (1) | WO2006045514A1 (zh) |
ZA (1) | ZA200703912B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
CN102695505A (zh) * | 2009-08-11 | 2012-09-26 | 阿勒根公司 | 用于治疗眼睛病症的异噻唑 |
WO2012130159A1 (zh) * | 2011-03-31 | 2012-10-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 氨基吡啶类衍生物及其用途 |
CN102099336B (zh) * | 2008-08-04 | 2013-11-06 | 默克专利有限公司 | 苯基氨基异烟酰胺化合物 |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
CN104334530A (zh) * | 2012-05-30 | 2015-02-04 | 默克专利股份公司 | N-((s)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺的固态形式 |
CN104788365A (zh) * | 2014-01-16 | 2015-07-22 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5214971B2 (ja) * | 2004-10-20 | 2013-06-19 | メルク セローノ ソシエテ アノニム | 3−アリルアミノピペリジン誘導体 |
EA032466B1 (ru) * | 2005-10-07 | 2019-05-31 | Экселиксис, Инк. | Способы получения ингибиторов mek |
BRPI0711625A2 (pt) * | 2006-04-19 | 2011-12-06 | Serono Lab | derivados de arilaminopiridina substituìda por heteroarila como inibidores de mek |
WO2007123939A2 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
JP2010500994A (ja) * | 2006-08-16 | 2010-01-14 | エグゼリクシス, インコーポレイテッド | Pi3kおよびmekモジュレーターを使用する方法 |
CN111643496A (zh) * | 2006-12-14 | 2020-09-11 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
DE102009004204A1 (de) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Verfahren zur verbesserten Bioaktivierung von Arzneistoffen |
EP2590951B1 (en) | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド |
WO2012007877A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体 |
EP2593428B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
ES2603032T3 (es) | 2010-07-15 | 2017-02-23 | Bayer Intellectual Property Gmbh | Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas |
JP2013542214A (ja) * | 2010-10-29 | 2013-11-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換フェノキシピリジン類 |
EA201491836A1 (ru) | 2012-04-06 | 2015-02-27 | Санофи | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek |
SG11201501923WA (en) | 2012-09-13 | 2015-04-29 | Hoffmann La Roche | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders |
AU2013328929B2 (en) * | 2012-10-12 | 2018-01-04 | Exelixis, Inc. | Novel process for making compounds for use in the treatment of cancer |
BR112015009777A2 (pt) | 2012-10-31 | 2017-07-11 | Fujifilm Corp | derivado de amina ou sal do mesmo |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
WO2014133071A1 (ja) | 2013-02-27 | 2014-09-04 | 第一三共株式会社 | Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 |
US10179132B2 (en) | 2015-05-26 | 2019-01-15 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same |
KR20160138756A (ko) * | 2015-05-26 | 2016-12-06 | 연세대학교 산학협력단 | 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법 |
AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
CA3041245C (en) | 2016-11-25 | 2022-12-06 | Shine Biopharma Inc. | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same |
CN111132673A (zh) | 2017-05-03 | 2020-05-08 | 维瓦斯治疗公司 | 非稠合三环化合物 |
KR101833412B1 (ko) | 2017-07-24 | 2018-02-28 | 연세대학교 산학협력단 | 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법 |
JP7245229B2 (ja) | 2017-08-21 | 2023-03-23 | ビバーチェ セラピューティクス,インク. | ベンゾスルホニル化合物 |
CA3084648A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
MA52093A (fr) | 2018-03-19 | 2021-01-27 | Taiho Pharmaceutical Co Ltd | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
WO2019183385A1 (en) * | 2018-03-22 | 2019-09-26 | University Of Rochester | Mapk/erk inhibition for ovarian and other cancers |
US11661403B2 (en) | 2018-05-16 | 2023-05-30 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
CN113473978A (zh) * | 2018-11-20 | 2021-10-01 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病氰基芳烃-苯胺化合物 |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
EP4134081A4 (en) | 2020-04-10 | 2024-05-01 | Taiho Pharmaceutical Co Ltd | CANCER THERAPY USING 3,5-DISUBSTITUTED ALCYNYL BENZENE COMPOUND AND MEK INHIBITOR |
JP2023551408A (ja) | 2020-11-16 | 2023-12-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | がん処置のためのキナーゼインヒビター組み合わせ |
US20240083844A1 (en) * | 2020-12-16 | 2024-03-14 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
WO2022207479A1 (en) | 2021-03-27 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2023089049A2 (en) | 2021-11-19 | 2023-05-25 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62223173A (ja) * | 1986-03-25 | 1987-10-01 | Otsuka Pharmaceut Factory Inc | ピリジルアミノフエノ−ル誘導体及びその製造方法 |
US4959378A (en) * | 1989-10-24 | 1990-09-25 | Hoechst-Roussel Pharmaceuticals Inc. | Aminopyridinylaminophenol compounds useful as topical antiinflammatory agents for the treatment of skin disorders |
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
DE69826662T2 (de) | 1997-07-01 | 2005-02-17 | Warner-Lambert Co. Llc | 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren |
AU2203900A (en) * | 1998-12-22 | 2000-07-12 | Warner-Lambert Company | Combination chemotherapy |
CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
CZ20012498A3 (cs) | 1999-01-13 | 2002-08-14 | Warner-Lambert Company | Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK |
IL144215A0 (en) * | 1999-01-13 | 2002-05-23 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
AU2482800A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
WO2000042003A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
IL147617A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
CA2408727A1 (en) * | 2000-05-22 | 2001-11-29 | Leo Pharma A/S | Benzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
BRPI0112584B8 (pt) * | 2000-07-19 | 2021-05-25 | Warner Lambert Co | ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação |
US20030073832A1 (en) * | 2001-04-10 | 2003-04-17 | Havez Sophie Elisabeth | Novel aminophenyl ketone derivatives |
JP2005528325A (ja) * | 2001-09-26 | 2005-09-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | C17,20リアーゼ阻害剤としての置換3−ピリジルインドール類およびインダゾール類 |
CA2463101A1 (en) | 2001-10-23 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Azole derivatives and pharmaceutical compositions containing them |
RU2300528C2 (ru) | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
EP2130536B1 (en) | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
EP1513840B1 (en) * | 2002-05-31 | 2006-10-04 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
US8178570B2 (en) * | 2003-04-09 | 2012-05-15 | Exelixis, Inc. | Tie-2 modulators and methods of use |
JP5214971B2 (ja) * | 2004-10-20 | 2013-06-19 | メルク セローノ ソシエテ アノニム | 3−アリルアミノピペリジン誘導体 |
EA032466B1 (ru) * | 2005-10-07 | 2019-05-31 | Экселиксис, Инк. | Способы получения ингибиторов mek |
-
2005
- 2005-10-19 JP JP2007537205A patent/JP5214971B2/ja active Active
- 2005-10-19 US US11/665,651 patent/US7956191B2/en active Active
- 2005-10-19 AU AU2005298932A patent/AU2005298932B2/en active Active
- 2005-10-19 AR ARP050104369A patent/AR051248A1/es active IP Right Grant
- 2005-10-19 PT PT57950305T patent/PT1802579E/pt unknown
- 2005-10-19 CN CN200580040688.5A patent/CN101065358B/zh active Active
- 2005-10-19 EA EA200700902A patent/EA013212B1/ru not_active IP Right Cessation
- 2005-10-19 PL PL05795030T patent/PL1802579T3/pl unknown
- 2005-10-19 EP EP05795030.5A patent/EP1802579B1/en active Active
- 2005-10-19 WO PCT/EP2005/011257 patent/WO2006045514A1/en active Application Filing
- 2005-10-19 ES ES05795030.5T patent/ES2444866T3/es active Active
- 2005-10-19 ZA ZA200703912A patent/ZA200703912B/xx unknown
- 2005-10-19 SI SI200531826T patent/SI1802579T1/sl unknown
- 2005-10-19 KR KR1020077011310A patent/KR101318012B1/ko active IP Right Grant
- 2005-10-19 CA CA2582247A patent/CA2582247C/en active Active
- 2005-10-19 MX MX2007004781A patent/MX2007004781A/es active IP Right Grant
- 2005-10-19 DK DK05795030.5T patent/DK1802579T3/da active
- 2005-10-19 UA UAA200704548A patent/UA94571C2/ru unknown
- 2005-10-19 BR BRPI0518192A patent/BRPI0518192B8/pt active IP Right Grant
-
2007
- 2007-05-21 NO NO20072595A patent/NO339639B1/no unknown
-
2008
- 2008-01-28 HK HK08101073.0A patent/HK1107347A1/zh unknown
-
2011
- 2011-05-20 US US13/112,490 patent/US8198457B2/en active Active
-
2012
- 2012-05-16 US US13/472,721 patent/US8524911B2/en active Active
-
2013
- 2013-07-11 US US13/940,065 patent/US8841459B2/en active Active
-
2014
- 2014-02-18 CY CY20141100121T patent/CY1114861T1/el unknown
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102099336B (zh) * | 2008-08-04 | 2013-11-06 | 默克专利有限公司 | 苯基氨基异烟酰胺化合物 |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
CN102695505A (zh) * | 2009-08-11 | 2012-09-26 | 阿勒根公司 | 用于治疗眼睛病症的异噻唑 |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US8637246B2 (en) | 2010-02-25 | 2014-01-28 | Dana-Farber Cancer Institute, Inc. | BRAF mutations conferring resistance to BRAF inhibitors |
US9279144B2 (en) | 2010-02-25 | 2016-03-08 | Dana-Farber Cancer Institute, Inc. | Screening method for BRAF inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
CN102718702A (zh) * | 2011-03-31 | 2012-10-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 氨基吡啶类衍生物及其用途 |
CN102718702B (zh) * | 2011-03-31 | 2015-01-07 | 中国人民解放军军事医学科学院毒物药物研究所 | 氨基吡啶类衍生物及其用途 |
WO2012130159A1 (zh) * | 2011-03-31 | 2012-10-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 氨基吡啶类衍生物及其用途 |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
CN104334530A (zh) * | 2012-05-30 | 2015-02-04 | 默克专利股份公司 | N-((s)-2,3-二羟基-丙基)-3-(2-氟-4-碘-苯基氨基)-异烟酰胺的固态形式 |
CN104788365A (zh) * | 2014-01-16 | 2015-07-22 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101065358A (zh) | 3-芳基氨基吡啶衍生物 | |
CN1252067C (zh) | 吲哚衍生物及其作为jnk调节剂的应用 | |
CN1297550C (zh) | 苯并呋喃衍生物及其制备和用途 | |
CN100339376C (zh) | 含氮芳环衍生物 | |
CN1142144C (zh) | 4-苯基-吡啶衍生物 | |
CN100340548C (zh) | 新型芳杂烷基胺衍生物 | |
CN1189467C (zh) | 药学活性磺酰胺衍生物 | |
CN1655779A (zh) | 取代的吲哚及其作为Raf激酶抑制剂的应用 | |
CN1805929A (zh) | 磷酸二酯酶4抑制剂 | |
CN1688573A (zh) | 糖原合成酶激酶3的吡咯基抑制剂 | |
CN1993361A (zh) | 用于治疗与血管发生有关的高增生性病症和疾病的吡咯并三嗪衍生物 | |
CN1839126A (zh) | 用于治疗癌症和其它病症的新的氰基吡啶衍生物 | |
CN1170827C (zh) | 苯并呋喃基吡喃酮衍生物 | |
CN1956982A (zh) | 具有氨基噻唑骨架的Cdk4、6选择性抑制剂 | |
CN1494541A (zh) | Erk2的杂环抑制剂及其应用 | |
CN1902196A (zh) | 噻唑衍生物 | |
CN1874769A (zh) | Mek的杂环抑制剂及其使用方法 | |
CN1681508A (zh) | 新型激酶抑制剂 | |
CN1325390A (zh) | 2-脲基噻唑衍生物及其制备方法和作为抗肿瘤剂的应用 | |
CN1507436A (zh) | 用作放射增敏剂和化疗增敏剂的芳基和杂芳基脲chk1抑制剂 | |
CN1791410A (zh) | 通过抑制jnk治疗或预防炎性或代谢性病症的方法 | |
CN1318057A (zh) | 用作cetp抑制剂的4-氨基取代的-2-取代的-1,2,3,4-四氢喹啉 | |
CN1328550A (zh) | 作为前列腺素e2激动剂或拮抗剂的噁唑化合物 | |
CN1642915A (zh) | 用作组蛋白脱乙酰基酶抑制剂的苯甲酰胺衍生物 | |
CN1518543A (zh) | 吡唑衍生物和它们作为蛋白激酶抑制剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1107347 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SERONO LABORATORY CO., LTD. Free format text: FORMER OWNER: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. Effective date: 20080516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080516 Address after: Swiss Coyne Hince Applicant after: Serono Lab Address before: Curacao, Netherlands Antilles Applicant before: Applied Research Systems ARS Holding N. V. |
|
ASS | Succession or assignment of patent right |
Owner name: MERCK SERONO CO., LTD. Free format text: FORMER OWNER: SERONO LABORATORIES LTD. Effective date: 20100324 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100324 Address after: Swiss Coyne Hince Applicant after: Merck Serono S. A. Address before: Swiss Coyne Hince Applicant before: Serono Lab |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1107347 Country of ref document: HK |